Medicine and Dentistry
Esophageal Squamous Cell Carcinoma
100%
Nivolumab
83%
Chemotherapy
79%
Ipilimumab
39%
Esophageal Cancer
37%
Overall Survival
36%
Sodium Fluoride
34%
Upper Gastrointestinal Cancer
22%
Disease
18%
Malignant Neoplasm
18%
Clinical Trial
17%
Tumor Cell
17%
Relative Survival
16%
Patient History of Chemotherapy
16%
Percutaneous Vertebroplasty
16%
Clinical Oncology
16%
Combination Therapy
16%
Radiation Therapy
16%
Systematic Review
16%
Lung Cancer
16%
Contouring
16%
Clinical Guideline
16%
Treatment Planning
16%
Mortality Rate
14%
Hazard Ratio
14%
Coronary Artery
12%
Volumetric Modulated Arc Therapy
12%
Programmed Death-Ligand 1
10%
Progression Free Survival
10%
Programmed Death 1 Ligand 1
9%
Artery
8%
Conservative Treatment
8%
Lung
8%
Cancer Incidence
8%
Patient Preference
8%
Abdominal Cancer
8%
Kyphoplasty
8%
Cancer
8%
Adverse Event
6%
Prevalence
6%
Cancer Registry
6%
Comorbidity
6%
ICD-10
6%
Patient-Data
5%
Cancer Staging
5%
Pharmacology, Toxicology and Pharmaceutical Science
Esophageal Squamous Cell Carcinoma
74%
Chemotherapy
57%
Nivolumab
50%
Esophagus Cancer
43%
Ipilimumab
39%
Sodium Fluoride
34%
Overall Survival
29%
Digestive System Cancer
22%
Neoplasm
18%
Chemoradiation Therapy
18%
Lung Cancer
16%
Biological Marker
16%
microRNA 375
16%
Combination Therapy
16%
Cetuximab
16%
Malignant Neoplasm
16%
Mortality Rate
14%
Disease Specific Survival
11%
Adenocarcinoma
10%
Progression Free Survival
9%
Programmed Death 1 Ligand 1
9%
Cancer Incidence
8%
Abdominal Cancer
8%
Fluorouracil
6%
Prevalence
6%
Comorbidity
6%
Cancer Registry
6%
ICD-10
6%
microRNA
5%
Cancer Staging
5%
Oxaliplatin
5%
Adverse Event
5%
Immunology and Microbiology
Squamous Cell
80%
Nivolumab
66%
Overall Survival
48%
Ipilimumab
40%
Tumor Cell
19%
Prognostic Biomarker
16%
Disease Specific Survival
16%
Esophagus
16%
Cetuximab
16%
Progression Free Survival
11%
Programmed Death 1 Ligand 1
10%
Programmed Death-Ligand 1
9%
